AbbVie Reaches Three-Year Deal with Trump Administration to Cut Drug Prices
AbbVie has announced a three-year agreement with the Trump administration to reduce drug prices, pledging $100 billion in research and development over the next decade. In return, AbbVie will receive tariff exemptions and protection from future pricing mandates.
Insights:
AbbVie Inc. has struck a significant three-year agreement with the Trump administration to reduce drug prices, marking a pivotal moment in the pharmaceutical industry's response to government pressure. Announced on January 12, 2026, the deal includes a pledge from AbbVie to invest $100 billion in research and development within the United States over the next decade. In exchange, the company will receive exemptions from tariffs and protection from future pricing mandates.
This agreement is part of a broader strategy by the Trump administration to address the high cost of prescription medicines in the United States, where prices are nearly three times higher than in other developed nations. The deal is structured to combine price reductions with substantial investment commitments and regulatory protections, setting a precedent for other pharmaceutical companies.
